3 'Perfect 10' Healthcare Stocks that Analysts Rate a Strong Buy!

three strong buy healthc care stocks, three perfect 10 smart scores, one just doubled its sales force, one just got upgraded to investment grade, and one just blew past earnings per share estimates by 38%. So, let's get into it. All right, guys, welcome back. Thank you all so much for being here. Today we are diving in to three healthc care stocks that all have a strong buy consensus from Wall Street analysts and score a 10 out of 10 on the tip rank smart score. That is a proprietary data set that looks at eight unique factors to measure a stock's likelihood to outperform the overall market. So today we're going to take a look at these companies, what it is that they do, and of course what Wall Street analysts have to say. If you enjoyed today's video, make sure you hit that thumbs up button and that you're subscribed to the channel. Now, let's dive right in. First up, we're taking a look at United Therapeutics. Their stock trades under the ticker UTR, currently priced at $531 per share. The stock has gained 76% in this past year, but is down more recently over 5%. They do score a 10 out of 10 on the tip rank smart score with increased hedge fund activity, very bullish new sentiment, and positive technicals. United Therapeutics is a biotech built around treating rare and life-threatening lung and cardiovascular disease, most notably pulmonary arterial hypertension. Its flagship franchise, Tvaso, is an inhaled therapy that's become the company's biggest revenue driver. But what makes United Therapeutics unique is its longshot bet on the future of medicine, xenotransplantation. engineering gene edited pig organs as a potential solution to the organ transplant shortage. They did just recently share a quarterly earnings report on August 4th and revenue was essentially flat and below expectations with their Tavaso facing real competitive pressure from a rival drug. Management also didn't reaffirm 2026 guidance which was a yellow flag but underneath that starts referrals and total patients all hit record highs. The sales force was roughly doubled heading into the second half, and the company posted multiple positive phase 3 readouts, plus new drug filings that could open up 2027 launches. Following that earnings report, we did have several analysts reiterate their buy ratings, but slightly lower price targets. One of those being an analyst at RBC Capital. They said that United Therapeutics reported Tobasso weakness with other quarterly declined and mis expectations, but investor focus remains on future growth drivers, including the IPF launch opportunity, Trey Smi, and RAL DPI pipeline progress. With nine current analyst ratings, the stock does come in as a strong buy with seven buys and two holds. The average price target is $655, implying an upside potential of over 23%. Looking at those recent ratings down below, they range from a downside of 3% to a high-end upside of 34%. Second on our list is Royalty Pharma, and this is a stock that we've touched on before. It trades under the ticker RPRX, currently priced at nearly $57 per share. The stock has climbed 52% in the past year and is up over 12% in the last 3 months. They score a 10 out of 10 on the tip rank smart score with increased hedge fund activity and very bullish new sentiment. Now, Royalty Pharma doesn't develop drugs, it buys the royalty rights to them. The company funds biioarma companies and academic institutions in exchange for a cut of future drug sales, building a diversified portfolio of royalties across dozens of approved and pipeline therapies. Think of it as a royalty collecting holding company for the drug industry. Royalty Pharma did also come out with some mixed results for their latest quarter on August 5th. While earnings per share beat by 5 cents, revenue missed by about 85 million, but did grow over 16% year-over-year. Their royalty receipts grew 14% year-over-year, and management raised fullear guidance to 3.4 to 3.5 billion. The company deployed 1.1 billion into new royalty acquisitions, including a stake in Astroenica's Ceramatug with Blockbuster Potential and got upgraded to investment grade credit by S&P in June. And following that earnings report, we have had several analysts increase their price targets, including an analyst at City. They view the company's Q2 report as solid and see meaningful upside to its growth outlook through 2030 from pipeline maturation. The stock does just have five current analyst ratings, but it does come in as a unanimous strong buy. The average price target of $66.50 implies an upside potential of nearly 17%. Looking at those analyst ratings down below, they range from an upside of 14% to nearly 23%. And for our third stock today, we're looking at GenMab. They trade under the ticker GMAB, currently priced above $31 per share. Their stock is up 39% over this past year and has gained nearly 13% in the last three months. Their 10 out of 10 smart score comes with positive crowd wisdom, very bullish new sentiment, and increased hedge fund activity with hedge funds increasing their shares by 2.3 million. Genmab is a Danish antibbody therapy company best known for co-developing two major cancer drugs. Darzalix, which is a multiple myyoma treatment partnered with Johnson and Johnson and a Pinley, a fast-growing lymphona bspecific antibbody partnered with Abby. It's a royalty and collaborationheavy model similar in spirit to Royalty Pharma, but layered on top of its own in-house drug discovery pipeline. They came out with both an earnings and revenue beat for their latest quarter, which just came out yesterday on August 6th. They crushed earnings per share estimates by nearly 38% and their Q2 revenue grew 23% year-over-year, beating by over 38.5 million. Management raised the fullear revenue guidance to 4.3 to 4.5 billion, and the company had a phase 3 readout for a key lymphoma combination hit its primary end point. And once again, we've seen some analysts increasing their price targets following that report with an analyst from Guggenheim simply noting that the company gave a robust Q2 result and raised their guidance. Genm has 10 current analyst ratings coming in as a strong buy with nine buys and one hold. And the average price target of nearly $39 implies an upside potential of almost 25%. Looking at the recent ratings down below, they range from an upside of 12% up to 38%. So, that is a quick look at three healthcare stocks, all with a strong by consensus and all with a 10 out of 10 on the Tip Rank Smart Score. Let me know your thoughts on these companies and which one catches your eye the most. I always appreciate hearing from you guys and keep in mind these videos are never a suggestion to buy or sell any specific stock, so always do your own research and due diligence. Thanks so much for watching. Have a wonderful day and I'll see you back here next time.